• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Introduction to 2-bromo-5,6-dimethoxy-1,3-benzothiazole (CAS No. 864169-36-8)

2-bromo-5,6-dimethoxy-1,3-benzothiazole, identified by the Chemical Abstracts Service Number (CAS No.) 864169-36-8, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the benzothiazole class, a scaffold widely recognized for its biological activity and versatility in drug design. The presence of bromine and methoxy substituents on the benzothiazole ring enhances its chemical reactivity, making it a valuable intermediate in synthetic chemistry and a potential candidate for further pharmacological exploration.

The structural features of 2-bromo-5,6-dimethoxy-1,3-benzothiazole make it an intriguing molecule for researchers studying novel therapeutic agents. The benzothiazole core is a fused system consisting of a benzene ring and a thiazole ring, which is known to exhibit various biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. The specific substitution pattern, with bromine at the 2-position and methoxy groups at the 5- and 6-positions, contributes to the unique electronic and steric properties of the molecule.

In recent years, there has been a surge in interest regarding heterocyclic compounds as pharmacophores due to their diverse biological activities and favorable pharmacokinetic profiles. 2-bromo-5,6-dimethoxy-1,3-benzothiazole has been explored in several preclinical studies as a potential lead compound for developing new drugs. Its brominated structure allows for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are commonly employed in drug discovery to introduce additional functional groups and improve bioavailability.

One of the most compelling aspects of 2-bromo-5,6-dimethoxy-1,3-benzothiazole is its potential application in targeting specific biological pathways. For instance, studies have suggested that benzothiazole derivatives can interact with enzymes and receptors involved in cancer progression. The bromine atom at the 2-position serves as a handle for palladium-catalyzed reactions, enabling the introduction of diverse substituents that may enhance binding affinity to biological targets. This flexibility makes it an attractive scaffold for structure-activity relationship (SAR) studies aimed at optimizing drug candidates.

Moreover, the methoxy groups at the 5- and 6-positions contribute to the lipophilicity of the molecule, which is a critical factor in drug absorption and distribution. By modulating these substituents, researchers can fine-tune the pharmacokinetic properties of 2-bromo-5,6-dimethoxy-1,3-benzothiazole to improve its suitability for therapeutic applications. This balance between hydrophobicity and hydrophilicity is essential for achieving optimal drug delivery and efficacy.

The synthesis of 2-bromo-5,6-dimethoxy-1,3-benzothiazole involves multi-step organic transformations that highlight its synthetic utility. The starting materials typically include commercially available precursors such as 2-aminothiophene-3-carboxylic acid derivatives or halogenated benzothiazoles. Through sequential bromination and methylation reactions under controlled conditions, high yields of the target compound can be obtained. These synthetic routes are well-documented in organic chemistry literature and provide a solid foundation for further modifications.

In academic research circles, 2-bromo-5,6-dimethoxy-1,3-benzothiazole has been employed as a building block in designing novel inhibitors targeting enzyme cascades involved in inflammatory diseases. For example, recent studies have demonstrated its potential as an antagonist of certain proteases implicated in chronic inflammation. By binding to these enzymes with high specificity, 2-bromo-5,6-dimethoxy-1,3-benzothiazole derivatives may offer therapeutic benefits comparable to existing anti-inflammatory drugs but with improved selectivity or reduced side effects.

The pharmaceutical industry has also shown interest in this compound due to its structural similarity to known bioactive molecules. Companies engaged in drug discovery often screen libraries of heterocyclic compounds for their ability to modulate biological pathways relevant to human health. 2-bromo-5,6-dimethoxy-1,3-benzothiazole fits well within this framework as it combines structural features that are both synthetically accessible and biologically relevant.

From a chemical biology perspective, understanding how 2-bromo-5,6-dimethoxy-1,3-benzothiazole interacts with biological targets is crucial for developing effective therapeutics. Computational modeling techniques have been increasingly used to predict binding affinities and optimize molecular interactions. These tools help researchers design derivatives with enhanced potency or selectivity by analyzing molecular docking simulations and predicting binding modes.

The environmental impact of synthesizing and using 2-bromo-5,6-dimethoxy-1,3-benzothiazole is another consideration that merits attention. While halogenated aromatic compounds are valuable intermediates in drug synthesis due to their reactivity and stability under various reaction conditions, their environmental fate must be carefully evaluated. Sustainable synthetic methodologies are being explored to minimize waste generation and reduce hazardous byproducts during production.

In conclusion,2-bromo-5,6-dimethoxy-1,3-benzothiazole (CAS No.864169-36-8) represents a promising compound with significant potential in pharmaceutical research. Its unique structural features enable diverse functionalization strategies while offering opportunities for targeting key biological pathways associated with various diseases. As research continues into novel heterocyclic scaffolds,2-bromo-<5,6-dimethoxy-<1,3-benzote) will likely play an important role in shaping future therapeutic developments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)